Barclays keeps Buy rating for Sandoz stock at CHF 93.00

Published on 10/09/2026 at 11:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock costs EUR 74.55 on October 9, 2026 after EUR 74.63. Sandoz plans a site visit for November 9, 2026.

Key points in brief

Barclays maintained a Buy rating on Sandoz with a CHF 93.00 price target dated October 6, 2026.
Sandoz stock was trading at EUR 74.55 at Lang & Schwarz on October 9, 2026, versus a prior close of EUR 74.63.
The company reported CHF 5.63 billion in quarterly revenue for the period ending June 30, 2026.
Sandoz is expanding biosimilar production in Slovenia and has scheduled a third-quarter update for October 28, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz (CH1243598427) was trading at EUR 74.55 at Lang & Schwarz on October 9, 2026 at 11:49 a.m. CEST, versus a prior close of EUR 74.63. The latest analyst signal came on October 6, when Barclays maintained a Buy rating and a CHF 93.00 price target, according to Markets Insider.

Revenue reached CHF 5.63 billion

For the quarter ending June 30, 2026, Sandoz reported revenue of CHF 5.63 billion and net profit of CHF 106.61 million, according to Markets Insider. Revenue was 6.83 percent above the CHF 5.27 billion reported for the comparable period, while net profit was below the CHF 377.00 million comparison figure.

The operating picture therefore contains two different signals: sales growth remains measurable, while earnings were lower on the reported comparison. That split gives the October 28 third-quarter update particular importance for assessing whether biosimilar growth is translating into stronger profitability.

Three expansion steps in 2026

On September 14, 2026, Sandoz issued a EUR 500 million bond with a 12-year maturity and a 4.835 percent coupon, according to EQS News.

On September 18, 2026, Health Canada approved Sandoz Semaglutide. The related market release cited close to 12 million semaglutide injection pens issued annually in Canada, according to EQS News.

On September 29, 2026, Sandoz opened its high-volume biosimilar drug substance center in Lendava, Slovenia. The facility employs over 300 experts and supports the company ambition of more than 100 biosimilars by 2040, according to EQS News.

What does the new plant change?

The Lendava investment adds manufacturing capacity inside Europe and gives the biosimilar strategy a physical operating base. The facility is also scheduled to host an investor and analyst site visit from November 9 to November 10, 2026, according to EQS News.

Key dates for the stock

Sandoz is expected to publish its third-quarter 2026 business update on October 28, 2026, as reported by MarketScreener. The same report cited Jefferies estimates of 6.10 percent third-quarter growth at constant exchange rates, with biosimilars expected to grow 20.00 percent.

EUR 74.55 in trading

Sandoz stock was trading at EUR 74.55 at Lang & Schwarz on October 9, 2026 at 11:49 a.m. CEST, down 0.11 percent versus the EUR 74.63 prior close at Lang & Schwarz on October 8, 2026. The reference price is in euros, while the analyst target and reported company figures above are in Swiss francs or the reporting currency named by their sources. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.